CCAR-066 (CBM.CD20 CAR-T) is under development for the treatment of chemotherapy resistant or refractory CD20+ leukemia and lymphoma including b-cell non-Hodgkin lymphoma, follicular lymphoma, mantle ...

T-cell large granular lymphocytic leukemia (T-LGLL) and T-cell prolymphocytic leukemia are rare hematologic malignancies. T-LGLL is caused by pro-inflammatory states, such as rheumatoid arthritis and ...

Tafasitamab (MOR-208, XmAb5574) is under development for the treatment of B cell malignancies including relapsed or refractory non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia ...

12, 2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

The treatment for leukemia depends on many factors ... These are synthetic versions that are designed to attack cancer cells. For CLL, monoclonal antibodies are a mainstay of treatment, often combined ...

For more than a decade, researchers, co-led by Gore’s team at Children’s, had studied the impact of the medication on B-cell acute lymphoblastic leukemia, the most common type of childhood cancer.

This accounts for 3% to 10% of all adult cases of non-Hodgkin's lymphoma. Mantle cell lymphoma is a subtype of B-cell non-Hodgkin’s lymphoma that primarily affects older adults. 1 While some ...

Jan. 15, 2025 — While most known types of DNA damage are fixed by our cells' in-house DNA repair mechanisms, some forms of DNA damage evade repair and can persist for many years, new research shows.